GILEAD SCIENCES TO TAKE OVER IMMUNOMEDICS FOR $21 BILLION

Highlights

• The company would issue a tender offer to purchase all the outstanding shares of Immunomedics for $88 per share that represent a premium of nearly 108% over their last closing price of $42.25 on Friday said Gilead

• Daniel O'Day, Chief Executive Officer Gilead, in his statement said that this acquisition represents significant progress in Gilead's work to build a strong and diverse oncology po....